Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GLAXF) EBIAT (2016 - 2025)

Historic EBIAT for Gsk (GLAXF) over the last 17 years, with Q4 2025 value amounting to $966.9 million.

  • Gsk's EBIAT fell 6841.27% to $966.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $8.3 billion, marking a year-over-year increase of 3446.74%. This contributed to the annual value of $8.3 billion for FY2025, which is 11985.91% up from last year.
  • Per Gsk's latest filing, its EBIAT stood at $966.9 million for Q4 2025, which was down 6841.27% from $2.9 billion recorded in Q3 2025.
  • Gsk's 5-year EBIAT high stood at $4.3 billion for Q4 2022, and its period low was $84.5 million during Q3 2024.
  • Over the past 5 years, Gsk's median EBIAT value was $2.1 billion (recorded in 2021), while the average stood at $2.2 billion.
  • Its EBIAT has fluctuated over the past 5 years, first plummeted by 9674.45% in 2024, then soared by 332475.32% in 2025.
  • Over the past 5 years, Gsk's EBIAT (Quarter) stood at $1.3 billion in 2021, then surged by 245.9% to $4.3 billion in 2022, then fell by 3.37% to $4.2 billion in 2023, then dropped by 26.94% to $3.1 billion in 2024, then plummeted by 68.41% to $966.9 million in 2025.
  • Its EBIAT was $966.9 million in Q4 2025, compared to $2.9 billion in Q3 2025 and $2.2 billion in Q2 2025.